Households exposed to COVID-19 now have an oral drug specifically cleared to prevent infection after contact with a sick ...

Detailed price information for Shionogi & CO Ltd (SGIOF) from The Globe and Mail including charting and trades.

Postexposure prophylaxis with nirmatrelvir-ritonavir for five or 10 days does not reduce the risk for symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a ...

Ensitrelavir significantly reduced the likelihood of developing symptomatic COVID-19 following household exposure compared with placebo. Treatment with ensitrelvir was found to prevent symptomatic ...

The U.S. Food and Drug Administration has approved Xocova (ensitrelvir), an oral antiviral, for postexposure prophylaxis (PEP) of COVID‑19 in adults and adolescents aged 12 years and older. Xocova is ...

A recent study published in JAMA Network Open evaluated the cost-effectiveness of monoclonal antibodies (mAbs) as pre-exposure prophylaxis (PrEP) for coronavirus disease 2019 (COVID-19). Study: Health ...

Please provide your email address to receive an email when new articles are posted on . The Infectious Disease Society of America suggests that immunocompromised patients take the COVID-19 prevention ...

HHS terminates COVID-19 Emergency Use Authorizations for drugs, biologics, and devices, establishing transition timelines toward traditional FDA pathways.

Detailed price information for Shionogi & CO Ltd (SGIOF) from The Globe and Mail including charting and trades.